Down syndrome and leukemia : from basic mechanisms to clinical advances
Baruchel, André (Hôpital Universitaire Robert Debré, Paris, France)
Bourquin, Jean Pierre (University Children's Hospital Zurich (Zúric, Suïssa))
Crispino, John (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica))
Cuartero, Sergi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Hasle, Henrik (Aarhus University Hospital (Aarhus, Dinamarca))
Hitzler, Johann (The Hospital for Sick Children, Toronto, Canada)
Klusmann, Jan Henning (Goethe University Frankfurt, Germany)
Izraeli, Shai (Tel Aviv University)
Lane, Andrew A. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Malinge, Sebastien (Cancer Centre, Perth, Western Australia)
Rabin, Karen R. (University of Oxford, UK)
Roberts, Irene (University of Oxford, UK)
Ryeom, Sandra (Columbia University Irving Medical Center, New York, USA)
Tasian, Sarah K. (University of Pennsylvania Perelman School of Medicine, Philadelphia, USA)
Wagenblast, Elvin (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))

Date:	2023
Abstract:	Children with Down syndrome (DS, trisomy 21) are at a significantly higher risk of developing acute leukemia compared to the overall population. Many studies investigating the link between trisomy 21 and leukemia initiation and progression have been conducted over the last two decades. Despite improved treatment regimens and significant progress in iden - tifying genes on chromosome 21 and the mechanisms by which they drive leukemogenesis, there is still much that is unknown. A focused group of scientists and clinicians with expertise in leukemia and DS met in October 2022 at the Jérôme Lejeune Foundation in Paris, France for the 1st International Symposium on Down Syndrome and Leukemia. This meeting was held to discuss the most recent advances in treatment regimens and the biology underlying the initiation, progression, and relapse of acute lymphoblastic leukemia and acute myeloid leukemia in children with DS. This review provides a summary of what is known in the field, challenges in the management of DS patients with leukemia, and key questions in the field.
Grants:	Agencia Estatal de Investigación PID2020-117950RA-I00 European Commission 714226
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Published in:	Haematologica, Vol. 108 Núm. 10 (october 2023) , p. 2570-2581, ISSN 1592-8721

DOI: 10.3324/haematol.2023.283225
PMID: 37439336

12 p, 4.8 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles